146 related articles for article (PubMed ID: 37500260)
21. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
22. Dose Mapping After Endoradiotherapy with
Hänscheid H; Lapa C; Buck AK; Lassmann M; Werner RA
J Nucl Med; 2018 Jan; 59(1):75-81. PubMed ID: 28588150
[TBL] [Abstract][Full Text] [Related]
23. SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post
Song H; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Nguyen J; Shah J; Iagaru A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2250-2257. PubMed ID: 36869177
[TBL] [Abstract][Full Text] [Related]
24. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
25. Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.
Gustafsson J; Brolin G; Cox M; Ljungberg M; Johansson L; Gleisner KS
Phys Med Biol; 2015 Nov; 60(21):8329-46. PubMed ID: 26458139
[TBL] [Abstract][Full Text] [Related]
26. Influence of sampling schedules on [
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
EJNMMI Phys; 2020 Jun; 7(1):41. PubMed ID: 32556844
[TBL] [Abstract][Full Text] [Related]
27. Imaging DNA Damage Repair In Vivo After
O'Neill E; Kersemans V; Allen PD; Terry SYA; Torres JB; Mosley M; Smart S; Lee BQ; Falzone N; Vallis KA; Konijnenberg MW; de Jong M; Nonnekens J; Cornelissen B
J Nucl Med; 2020 May; 61(5):743-750. PubMed ID: 31757844
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
29. Kidney dosimetry during
Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
[TBL] [Abstract][Full Text] [Related]
30. In Vivo Instability of
Lubberink M; Wilking H; Öst A; Ilan E; Sandström M; Andersson C; Fröss-Baron K; Velikyan I; Sundin A
J Nucl Med; 2020 Sep; 61(9):1337-1340. PubMed ID: 32005767
[TBL] [Abstract][Full Text] [Related]
31. Radiation exposure after
Mair C; Warwitz B; Fink K; Scarpa L; Nilica B; Maffey-Steffan J; Buxbaum S; Virgolini IJ
Ann Nucl Med; 2018 Aug; 32(7):499-502. PubMed ID: 29797003
[TBL] [Abstract][Full Text] [Related]
32. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract][Full Text] [Related]
33. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
34. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
35. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
36. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in (177)Lu-DOTATATE peptide receptor radionuclide therapy.
Brolin G; Gustafsson J; Ljungberg M; Gleisner KS
Phys Med Biol; 2015 Aug; 60(15):6131-49. PubMed ID: 26215085
[TBL] [Abstract][Full Text] [Related]
38. Quantitative SPECT/CT Imaging of (177)Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy.
Sanders JC; Kuwert T; Hornegger J; Ritt P
Mol Imaging Biol; 2015 Aug; 17(4):585-93. PubMed ID: 25475521
[TBL] [Abstract][Full Text] [Related]
39. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
40. Particle filter de-noising of voxel-specific time-activity-curves in personalized
Götz TI; Lang EW; Schmidkonz C; Maier A; Kuwert T; Ritt P
Z Med Phys; 2020 May; 30(2):116-134. PubMed ID: 31859029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
